Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Recruiting now · Phase 1

Conditions studied: Age-Related Macular Degeneration

In brief

This open-label study is being conducted to evaluate the initial safety and tolerability of BBC1501 IVT in patients with nAMD. The primary objective of this study is to evaluate the safety and tolerability of 3 ascending doses of IVT BBC1501 in patients with nAMD. The secondary objective of this study is to exploratory of BBC1501 efficacy following 3 ascending dose of BBC1501 in nAMD patient.

Key facts

Study ID

NCT05803785

Run by

Benobio Co., Ltd.

People needed

18

Starts

2025-07-01

Expected to finish

2026-12-01

Last updated by the study team

2026-05-15

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Sydney Hospital — Sydney, Australia (enrolling)
• Benobio Investigational site — Sydney, New South Wales, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.